OMDA
Neutral signalScored 2026-10-07 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Omada Health
- Nom
- Omada Health
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NASDAQ
- Capitalisation
- $1.2B
- Employés
- 946
- PDG
- Sean Duffy
- Site web
- https://www.omadahealth.com
- Marché
- AMWLHIMSHNGETDOC
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 53 790 titres (~1 180 451,06 $ US)
- Insiders
- Duffy Sean P.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,628,511
Avg sell (VWAP, 90d window) $23.56 vs last close $20.89 (-11.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,628,511 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $31,046,520/day · 20d vol
- Last synced
-
2026-10-07 21:10:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Duffy Sean P. | Sell · S · 10b5-1 | 4,314 | $20.90 | $90,163 | Form 4 |
| 2026-09-10 | Cook Steven L. | Sell · S · 10b5-1 | 600 | $22.52 | $13,510 | Form 4 |
| 2026-09-10 | Duffy Sean P. | Sell · S · 10b5-1 | 1,400 | $22.59 | $31,628 | Form 4 |
| 2026-09-10 | Shao Wei-Li | Sell · S · 10b5-1 | 400 | $22.53 | $9,013 | Form 4 |
| 2026-09-09 | Gracey Craig | Sell · S · 10b5-1 | 644 | $21.73 | $13,995 | Form 4 |
| 2026-09-01 | Duffy Sean P. | Sell · S · 10b5-1 | 3,695 | $24.27 | $89,682 | Form 4 |
| 2026-08-27 | Cook Steven L. | Sell · S · 10b5-1 | 1,108 | $25.00 | $27,700 | Form 4 |
| 2026-08-12 | Shao Wei-Li | Sell · S · 10b5-1 | 8,866 | $25.02 | $221,798 | Form 4 |
| 2026-08-11 | Cook Steven L. | Sell · S · 10b5-1 | 1,607 | $25.01 | $40,197 | Form 4 |
| 2026-08-10 | Cook Steven L. | Sell · S · 10b5-1 | 15,235 | $25.03 | $381,350 | Form 4 |
| 2026-08-10 | Gracey Craig | Sell · S · 10b5-1 | 1,042 | $25.00 | $26,050 | Form 4 |
| 2026-08-10 | Duffy Sean P. | Sell · S · 10b5-1 | 12,942 | $24.81 | $321,059 | Form 4 |
| 2026-08-07 | Duffy Sean P. | Sell · S · 10b5-1 | 4,314 | $22.80 | $98,359 | Form 4 |
| 2026-08-03 | Duffy Sean P. | Sell · S · 10b5-1 | 12,944 | $20.40 | $264,007 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-07 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
OMDA presents a solid liquidity foundation (score 85) with a debt-free balance sheet and strong gross margins, but the weak catalyst score (35) driven by heavy insider selling of $1.18M with zero buys significantly…
The first sentence of the analysis written for OMDA on 2026-10-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.6M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.6M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Unavailable or mixed. Current ratio 3.60 · operating margin -4.6% — readings disagree
Suggested stop 19.93, nearest stored support minus 0.5 ATR(4.6% under the last close). Reward/risk to the next stored resistance is 3.69. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.7% | 60.6% | 57.0% | 48.0% | |
| Ebit Margin | -3.9% | -25.1% | -51.2% | -76.6% | |
| Ebitda Margin | -1.8% | -22.3% | -47.5% | -71.7% | |
| Operating Profit Margin | -4.6% | -25.7% | -53.8% | -81.1% | |
| Pretax Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Continuous Operations Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Net Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Bottom Line Profit Margin | -4.9% | -27.8% | -55.0% | -81.3% | |
| Current Ratio | 3.604 | 2.096 | 3.263 | 5.463 | |
| Quick Ratio | 3.545 | 2.034 | 3.180 | 5.361 | |
| Solvency Ratio | -0.096 | -0.491 | -0.828 | -1.030 | |
| Cash Ratio | 2.932 | 1.416 | 2.641 | 4.871 | |
| Price To Earnings Ratio | -71.727 | -27.059 | -19.008 | -17.692 | |
| Price To Earnings Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Price To Earnings Diluted Ratio | -71.727 | -27.059 | -19.008 | -17.692 | |
| Price To Earnings Diluted Growth Ratio | 0.968 | 0.909 | 2.746 | 0.000 | |
| Price To Book Ratio | 4.014 | 19.838 | 12.961 | 8.240 | |
| Price To Sales Ratio | 3.543 | 7.551 | 10.442 | 14.376 | |
| Price To Free Cash Flow Ratio | 54.460 | -33.703 | -24.348 | -17.881 | |
| Price To Operating Cash Flow Ratio | 50.516 | -37.512 | -25.777 | -18.587 | |
| Debt To Assets Ratio | 0.000 | 0.200 | 0.175 | 0.139 | |
| Debt To Equity Ratio | 0.000 | 0.467 | 0.309 | 0.198 | |
| Debt To Capital Ratio | 0.000 | 0.318 | 0.236 | 0.165 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.315 | 0.229 | 0.157 | |
| Financial Leverage Ratio | 1.330 | 2.335 | 1.770 | 1.425 | |
| Working Capital Turnover Ratio | 2.030 | 2.147 | 0.970 | 0.000 | |
| Operating Cash Flow Ratio | 0.241 | -0.633 | -1.136 | -1.999 | |
| Operating Cash Flow Sales Ratio | 0.070 | -0.201 | -0.405 | -0.773 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.928 | 1.113 | 1.059 | 1.039 | |
| Debt Service Coverage Ratio | -1.876 | -8.395 | -12.403 | -15.231 | |
| Interest Coverage Ratio | -4.725 | -9.688 | -14.027 | -17.222 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -1.132 | -1.626 | -2.239 | |
| Capital Expenditure Coverage Ratio | 13.806 | -8.848 | -17.028 | -25.351 | |
| Dividend Paid And Capex Coverage Ratio | 13.806 | -8.848 | -17.028 | -25.351 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -147.270 | -32.672 | -20.512 | -17.892 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 65.7% | ▲5.1% | ▲7.9% |
| Ebit Margin | -3.9% | ▲21.2% | ▲35.3% |
| Ebitda Margin | -1.8% | ▲20.4% | ▲34.0% |
| Operating Profit Margin | -4.6% | ▲21.1% | ▲36.7% |
| Pretax Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Continuous Operations Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Net Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Bottom Line Profit Margin | -4.9% | ▲22.9% | ▲37.3% |
| Current Ratio | 3.604 | ▲1.509 | ▼-0.002 |
| Quick Ratio | 3.545 | ▲1.511 | ▲0.015 |
| Solvency Ratio | -0.096 | ▲0.395 | ▲0.515 |
| Cash Ratio | 2.932 | ▲1.516 | ▼-0.033 |
| Price To Earnings Ratio | -71.727 | ▼-44.668 | ▼-37.856 |
| Price To Earnings Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Forward Price To Earnings Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Price To Earnings Diluted Ratio | -71.727 | ▼-44.668 | ▼-37.856 |
| Price To Earnings Diluted Growth Ratio | 0.968 | ▲0.058 | ▼-0.188 |
| Price To Book Ratio | 4.014 | ▼-15.823 | ▼-7.249 |
| Price To Sales Ratio | 3.543 | ▼-4.007 | ▼-5.435 |
| Price To Free Cash Flow Ratio | 54.460 | ▲88.163 | ▲59.828 |
| Price To Operating Cash Flow Ratio | 50.516 | ▲88.028 | ▲58.356 |
| Debt To Assets Ratio | 0.000 | ▼-0.200 | ▼-0.128 |
| Debt To Equity Ratio | 0.000 | ▼-0.467 | ▼-0.243 |
| Debt To Capital Ratio | 0.000 | ▼-0.318 | ▼-0.180 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.315 | ▼-0.175 |
| Financial Leverage Ratio | 1.330 | ▼-1.005 | ▼-0.385 |
| Working Capital Turnover Ratio | 2.030 | ▼-0.116 | ▲0.744 |
| Operating Cash Flow Ratio | 0.241 | ▲0.875 | ▲1.123 |
| Operating Cash Flow Sales Ratio | 0.070 | ▲0.271 | ▲0.398 |
| Free Cash Flow Operating Cash Flow Ratio | 0.928 | ▼-0.185 | ▼-0.107 |
| Debt Service Coverage Ratio | -1.876 | ▲6.519 | ▲7.601 |
| Interest Coverage Ratio | -4.724 | ▲4.963 | ▲6.691 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲1.132 | ▲1.249 |
| Capital Expenditure Coverage Ratio | 13.806 | ▲22.654 | ▲23.161 |
| Dividend Paid And Capex Coverage Ratio | 13.806 | ▲22.654 | ▲23.161 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -147.270 | ▼-114.598 | ▼-92.683 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $922.0M | $1.28B | $1.28B | $1.28B | |
| Enterprise value | $700.0M | $1.24B | $1.20B | $1.14B | |
| EV / Sales | 2.69x | 7.28x | 9.75x | 12.84x | |
| EV / Op. cash flow | 38.35x | -36.16x | -24.07x | -16.60x | |
| EV / Free cash flow | 41.34x | -32.49x | -22.73x | -15.97x | |
| EV / EBITDA | -147.27x | -32.67x | -20.51x | -17.89x | |
| Net debt / EBITDA | 46.72x | 1.22x | 1.46x | 2.15x | |
| Current ratio | 3.60x | 2.10x | 3.26x | 5.46x | |
| Income quality | -1.43x | 0.72x | 0.74x | 0.95x | |
| Graham net-net | $3 | $0 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 124.7% | 110.6% | 107.5% | 106.1% | |
| Working capital | $197.2M | $59.1M | $99.1M | $154.0M | |
| Invested capital | $220.8M | $82.7M | $124.2M | $181.7M | |
| Return on assets | -4.2% | -31.2% | -38.6% | -32.7% | |
| Operating ROA | -5.2% | -26.8% | -33.3% | 0.0% | |
| Return on tangible assets | -4.4% | -35.3% | -43.4% | -36.2% | |
| Return on equity | -5.6% | -72.9% | -68.2% | -46.6% | |
| Return on invested capital | -5.2% | -44.8% | -50.0% | -38.5% | |
| Return on capital employed | -5.2% | -45.0% | -50.3% | -38.6% | |
| Earnings yield | -1.4% | -3.7% | -5.3% | -5.7% | |
| Free cash flow yield | 1.8% | -3.0% | -4.1% | -5.6% | |
| Capex / Op. cash flow | 7.2% | -11.3% | -5.9% | -3.9% | |
| Capex / Depreciation | 24.1% | 80.4% | 65.7% | 62.8% | |
| Capex / Sales | 0.5% | 2.3% | 2.4% | 3.1% | |
| SG&A / Sales | 54.7% | 65.1% | 83.3% | 99.8% | |
| R&D / Sales | 15.6% | 21.2% | 27.5% | 29.3% | |
| Stock comp / Sales | 5.0% | 5.5% | 7.1% | 7.5% | |
| Intangibles / Total assets | 5.1% | 11.6% | 11.1% | 9.7% | |
| Days sales outstanding | 49d | 51d | 49d | 48d | |
| Days payables outstanding | 42d | 23d | 25d | 32d | |
| Operating cycle | 67d | 69d | 74d | 76d | |
| Cash conversion cycle | 25d | 47d | 49d | 43d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Reviewing HCA Healthcare (NYSE:HCA) & Omada Health (NASDAQ:OMDA) HCA Healthcare (NYSE: HCA - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Earnings and Valuation This table compares HCA Healthcare
- 2026-09-28 Omada Health, Inc. (NASDAQ:OMDA) Stock Has Average Price Target of $26.67 Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the
- 2026-09-28 Bank of America Corp DE Acquires 313,440 Shares of Omada Health, Inc. $OMDA Bank of America Corp DE acquired a new stake in Omada Health, Inc. (NASDAQ: OMDA) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 313,440 shares of the company''s stock, valued at approximately $6,880,000. Bank of America Corp DE owned approximately 0.51% of
- 2026-09-26 Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast NeoGenomics (NASDAQ: NEO - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Risk and Volatility NeoGenomics has a beta of 1.75,
- 2026-09-23 Omada Health President Wei-Li Shao Sells 9,418 Shares for $236,000 The transaction represented 3% of the insider''s direct equity holdings before the filing. The sale was conducted directly through an open-market transaction under a pre-established Rule 10b5-1 trading plan.
- 2026-09-11 Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
- 2026-09-10 Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day SAN FRANCISCO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, will present its long-term financial targets at the company''s inaugural Investor Day, being held today at the Four Seasons Hotel in New York, New York.
- 2026-09-09 Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada''s GLP-1 Program SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada''s GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease reduction and higher cumulative cost savings with Omada''s GLP-1 solutions compared to standard care.
- 2026-09-09 Insider Alert: Omada Health CEO Sean Duffy Sells 31,457 Shares Traded 31,457 shares with a transaction value of ~$735,150 based on a weighted average price of $23.37 per share. The activity involved shares equal to 2% of the total equity stake held before the filing, including direct transactions equal to 8% of the prior direct position.
- 2026-09-03 Omada Health, Inc. (NASDAQ:OMDA) Receives $26.50 Average PT from Brokerages Shares of Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation